



**HAL**  
open science

## **B. thuringiensis – identification, biology and uses**

Vincent Sanchis-Borja

► **To cite this version:**

Vincent Sanchis-Borja. B. thuringiensis – identification, biology and uses. École thématique. Bacillus – identification, phylogeny and potential pathogenicity, Department of Environmental Science, Aarhus University, Roskilde, Denmark, Denmark. 2019. hal-04338623

**HAL Id: hal-04338623**

**<https://hal.inrae.fr/hal-04338623>**

Submitted on 12 Dec 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



## *B. thuringiensis* – identification, biology and uses


Vincent Sanchis-Borja

HuPlant(Cost Action 16110) training School

# The *Bacillus cereus sensu lato* group

Gram<sup>+</sup>, sporulating, low GC% (35%) bacteria

Set of common genes represent ~ 75% of the genome (~ 4 Mb)



*Bacillus thuringiensis*  
specific genes



A biopesticide  
agent


*Bacillus cereus*  
specific genes



A food borne pathogen

A typical *B. cereus s. l.* genome contains  
~5500 protein coding genes

*Bacillus anthracis*  
specific genes







A bioterrorism  
agent

Harbors a diverse range of plasmids that vary in number and in size (2–200kb)

The specific pathogen properties of these bacteria are due to plasmid


# What is *Bacillus thuringiensis* ?

- Common soil bacterium
- Present in nature in a variety of forms (strains)
- Characterized by the production of crystal inclusions containing proteins (Cry toxins) that are toxic to insects
- Isolates frequently produce crystals containing multiple Cry proteins.
- Commonly used for commercial agriculture, including organic farming
- Extremely well-known toxin in terms of human health & environmental safety



Free spores & crystals in technical powder

## Identification of *Bacillus thuringiensis* strains



Photomicrographs of *Bacillus thuringiensis* strains viewed by phase-contrast microscopy showing the parasporal crystals of insecticidal toxins (green arrows) or spores (red arrows)

## *Bacillus thuringiensis* (Bt) historical background

- **1901** : Discovered in silkworm by the Japanese bacteriologist Ishiwata “Sottokin”.
- **1911** : A new isolation by Berliner on *Ephestia kuehniella* (Zeller) larvae from Thuringe (Germany)
- **1938** : First commercial preparation (Sporéine) by Libec Laboratories in France.
- **1956** : development of an industrial process known as submerged fermentation, by the Pacific Yeast Product Company, which allowed production of Bt on a large scale.
- **1960** : First commercial use in the United State.
- **1977** : Discovery of *Bacillus thuringiensis* var. *israelensis* toxic to flies by Goldberg and Margalit
- **1981** : first cloning of a *Cry* gene
- **1983** : discovery, of *Bacillus thuringiensis* var. *tenebrionis* toxic to beetles by Krieg
- **1985** : First insect resistant transgenic plant
- **1990** : strain and cry gene isolation: several tens of thousands of isolates yielding over 250 distinct Cry proteins
- **1995**: First Bt transgenic plant commercialised in USA
- **2017**: 100 millions hectares of biotech crops with insect resistance Bt genes were planted all over the world, grown by up to 17 million farmers globally in 2017

# Insecticidal activity of *Bacillus thuringiensis* strains

- Bt is a highly heteromorphous comprising a very large number of strains distributed in more than 70 serotypes, including various *subspecies*: *kurstaki*, *tenebrionis*, *israelensis*... with various pathogenic activities against insect larvae from different orders

*lepidoptera*



*coleoptera*




*diptera (mosquitoes)*



or against nematodes




or against cancer cells



or with yet unknown activity

# Crystal toxin description

*Bt* isolates frequently produce crystals containing multiple Cry proteins.



## *B. thuringiensis* subsp. *Kurstaki*


Bipyramidal crystals of Cry1Aa, Cry1Ab, and Cry1Ac  
and  
Cuboidal crystal of Cry2A.

## *B. thuringiensis* subsp. *israelensis*


Large semispherical inclusion of Cyt1Aa,  
and  
Dense spherical body of Cry4Aa and Cry4Ba  
and.  
Bar-shaped body of Cry11Aa







# Crystal protein content analysis



# Crystal toxins classification



Gene	Crystal shape	Protein size (kDa)	Insecticidal activity
<i>cry1</i> (A,B,... and a,b,...)		130-138	Lepidoptera
<i>cry2</i>		69-71	Lepidoptera and Diptera
<i>cry3</i>		73-74	Coleoptera
<i>Cry4, cry11</i>		73-134	Diptera

Hofte and Whiteley, 1989

# Classification of the Cry toxins

Bt toxicity is due to the Cry proteins

These Cry toxins consist in a very large protein family. There are classified as follows:

Rank 1: 74 classes: Cry1, 2..., 74


Rank 2: ~ 300 subclasses: Cry1A, B, C...

Rank 3: > 500 alleles: Cry1Aa, b, c, d...

Together, these toxins allow to kill:

- ✓ Various insect larvae (lepidoptera, Cry1, 2...; coleoptera, Cry3, 8...; mosquitoes, Cry4, 11...)
- ✓ Nematodes (Cry5, 6...)
- ✓ Cancer cells (Cry41, 45...)

dendrogram describing the relatedness of the toxins which share the common three-domain



# Summarized view showing the known host spectrum of Bt Cry toxins

Cry1A-K; Cry2A  
Cry7B; Cry8D  
Cry9A-C,E; Cry15A  
Cry22A; Cry32A  
Cry51A



**Lepidoptera**



**Diptera**

Cry1A-C; Cry2A  
Cry4A-B; Cry10  
Cry11A-B; Cry16A  
Cry19A-B; Cry20A  
Cry24C; Cry27A  
Cry32B-D; Cry39A  
Cry44A; Cry47A  
Cry48A; Cry49A  
Cyt1A-B; Cyt2A-B



**Coleoptera**


Cry1B, I; Cry3A-C; Cry7A  
Cry8A-G; Cry9D; Cry14A  
Cry18A; Cry22A-B; Cry23A  
Cry34A-B; Cry35A-B; Cry36A  
Cry37A; Cry43A-B; Cry55A  
Cyt1A; Cyt2C

Cry5A-B; Cry6A-B  
Cry12A; Cry13A  
Cry14A; Cry21A  
Cry55A




**Rhabditida**

**$\delta$ -Endotoxins**



Cry31A  
Cry41A  
Cry42A  
Cry45A  
Cry46A



**Human-cancer  
cells**

Cry2A  
Cry3A  
Cry11A



**Hemiptera**

Cry3A  
Cry5A  
Cry22A



**Hymenoptera**





Cry1Ab



**Gastropoda**

Palma *et al.*, 2014

# Crystal toxin structure: 3 domains structure



**Domain I** seven helix bundles



**Domain II** triple anti-parallel  $\beta$  sheets

**Domain III**  $\beta$ -sheet sandwich

❑ The long, hydrophobic and amphipathic  $\alpha$  helices of Domain I is equipped for transmembrane pore formation.

❑ The  $\beta$  sheet structure of domain II and domain III are involved in receptor binding and specificity determination.


# Crystal gene structure: 5 conserved domains



# Mode of action of the Cry toxins


- Most Cry toxins are synthesized as inactive protoxins.
- Conversion of the protoxin (e.g., 130 kDa) into the active toxin (e.g., 68 kDa) requires the combination of a slightly alkaline pH (7.5-8) and the action of a specific protease(s) found in the insect gut

:




- The active toxin binds to protein receptors on the insect gut epithelial cell membrane
- The toxin forms an ion channel between the cell cytoplasm and the external environment, leading to loss of cellular ATP gut wall to break down, allowing spores and normal gut bacteria to enter the body.
- The insect dies as spores and gut bacteria proliferate in the body.

# Schematic mode of action of the Cry toxins






## Effect of insecticidal toxins on epithelial cells




Appical Microvilli  
(control)



Swelling of cells and lysis  
(2 hours post intoxication),


# Regulation of *cry* gene expression



*cry1* (lepidopteran), *cry4* and *cry11* (dipteran) and *cry2* (dipteran and lepidopteran) genes are controlled by sporulation sigma factors whereas *cry3* (coleopteran) is not


# Post-transcriptional regulation

- The half life of general mRNA is about 2-3 min (Nilsson *et al.*, 1984).
- *cry1* mRNAs have half lives of about 10 min (Glatron and Rapaport, 1972).
- Terminator of most *cry1* genes contain large inverted repeats which are capable to form stem loop and protect the mRNA from 3' ribonuclease degrading enzymes.
- A Shine Dalgarno sequence (STAB-SD) in the 5' untranslated region acts as a 5' mRNA stabilizer.
- These characteristics increase *cry* mRNA stability.



The STAB-SD sequence in *cry3A* mRNA. The 30S ribosomal subunit can bind to the STAB-SD sequence mRNA and block the further 5' → 3' exoribonucleolytic progress of RNase J1.

Agaisse and Lereclus 1996




The secondary structure at the 3' end of *cry1Aa* gene mRNA from *B. thuringiensis* subsp. *kurstaki* HD1


Wong and Chang, 1986

# Biocontrol Market stats


## 2015 Biocontrol Market




## 2015 Biopesticide Market




## 2015 Biopesticide Market



# *B. thuringiensis* and its uses as a biological control agent





Outdoor residential areas



# Current market for Bt pesticides



Biocontrol products today hold just 5% to 6% of the total crop protection market of approximately \$50 billion in value worldwide, and 60% of all biopesticides use consists of Bt-based products.



## Advantages of *Bt* Bioinsecticides

- Because for the toxin to be effective it has to be ingested, this limits the susceptibility of none target insects and other animals to this insecticide.
- Highly-specific compared to many synthetic insecticides -> Btk, Bta: Lepidopteran larvae only
- Safe to users, livestock, wildlife mammals have acidic gut
- Highly compatible with Integrated Risk Management (IPM)
- No effect on beneficial insects
- No toxic residues

## Limitations of *Bt* Bioinsecticides

- High specificity = narrow spectrum -> ineffective against many key pests (i.e., aphids, mites, thrips, etc)
- *B. thuringiensis* toxin can only kill a susceptible insect during a specific developmental stage.
- Most effect against young larvae -> Proper timing of sprays is critical L1-L2 best; L3-maybe; L4-L5-too late. No effect on eggs, pupae, adults
- Sensitive to environmental conditions : Solar UV radiation (spray late in day, use sunscreen) Alkaline water (high pH)
- No contact activity -> Must be ingested to be effective Good spray coverage is critical to success
- Insects that attack plant roots are less likely to ingest a *B. thuringiensis* toxin that has been sprayed on the surface of a host plant.



## Some desirable features of new genetically engineered and improved *Bt* products

- ***Broadened host range or optimized activity on a desired target insect***

To maximize market size or to target a selected niche

- ***Increased persistence***

To reduce the need for regular applications

- ***Improved potency***

To achieve the desired effect in a cost effective manner

- ***Sporulation deficient mutants***

To minimize possible unforeseen environmental effects arising from the dissemination of large amounts of viable spores




- ***Recombinant strains free of non-Bt DNA or antibiotic resistance genes***

To facilitate regulatory approval for environmental release and/or registration as a biopesticide

# Development of safer and more effective Bt-Based biopesticides



## Objectives :

- Design new biopesticides and validate the relevance of these products and their performance, while ensuring better security of use for farmers, consumers and the environment.
- Improve Bt strains used as biopesticides by increasing their efficiency and persistence in the environment while avoiding the spread of viable spores in the environment




# Construction of an asporogenic non viable of *B. thuringiensis* strain

Expression of *cry1A'*lacZ and *cry3A'*lacZ transcriptional fusions in two different genetic backgrounds: WT (A) and  $\Delta spoOA$  (B)



Longitudinal section of Bt WT producing large amounts of Cry1A at the end of sporulation before cell lysis.



Longitudinal section of a Bt  $\Delta spoOA$  strain producing large amounts of Cry3A during the stationary phase.

The transcription of the *cry3A* gene is independent of the regulatory genes involved in the sporulation process

## Necessary steps for obtaining insect-resistant transgenic plants

- Introduction of cry genes into plant cells
  - => Transformation by *Agrobacterium* or direct gene transfer in the plant cell (transformation of protoplasts, particle guns)
- Expression of cry genes in the host plant
  - => genes with Eukaryotic structure (synthetic genes)
- Integration of cry genes into the host genome
  - => Stable and transmissible expression to daughter cells of the transgene
- Selection and regeneration of whole plants from genetically modified cells
  - => Efficient transfer, use of selection markers, obtaining an entire organism from selected transformants

## Construction of a transgenic tobacco transformed with the *cry1C* gene



On the left, the untransformed control. On the right is tobacco transformed with a *cry1C* gene modified for expression in plants. In both cases 40 larvae of *S. littoralis* were deposited on the leaves. Damage observed after 72 hours. (Photo: J. Tourneur, INRA)

# Commercialized transgenic plants resistant to insects



**Cotton:** 1<sup>st</sup> commercialised in 1996

- in 2017: 14 countries;

18 million hectares IR and 5.2 million hectares IR/HT

77% of the global cotton area

12,8% of the global biotech crop area



**Maize:** 1st commercialised in 1996

- in 2017: 14 countries

5.3 million hectares IR and 48.1 million hectares stacked IR/HT

28,6 % of the global maize area

28,1 % of the global biotech crop area



**Soybean:** 1st commercialised in 1996

- in 2017: 9 countries

24.4 million million hectares stacked IR/HT

20 % of the global soybean area


12,8% of the global biotech crop area



**Potato:** first commercialised in 1996, withdrawn in 2001

# Distribution of traits of approved GM events


HT - Herbicide Tolerance;  
IR - Insect Resistance;  
DR - Disease Resistance;  
PC -Pollination Control;  
PQ - Modified Product Quality:




Source: ISAAA, 2017

# Distribution of biotech crops by crop and by trait (million hectares)

## Global Area of Biotech Crops, 1996 to 2017: by Trait (Million Hectares)



## Global Adoption Rates (%) for principal biotech crops in 2017






# The cultivation of Bt plants is widely spread

Global Adoption Rates (%) for principal Bt crops in 2017

Bt Plants	% USA	% World
Corn	87	29
Cotton	88	77
Soybean	0*	20

\* In the US only Herbicide tolerant soybean is grown

In USA, in the period of 1995-2010, the amount of pesticides used per acre of corn decreased by 99%, while insecticide use on cotton crops reduced approx. 95%.



## Global crop protection market in 2017

US\$M	Herbicides	Insecticides	Fungicides	Others	Biotech	Total
North America	5,772	2,287	2,298	442	12,398	23,197
Europe	5,312	1,672	4,412	396	10	11,622
Japan	1,100	1,089	880	62	0	3,131
Australia	562	196	150	22	35	965
<b>Industrial Countries</b>	<b>12,566</b>	<b>5,244</b>	<b>7,740</b>	<b>922</b>	<b>12,443</b>	<b>38,915</b>
Latin America	5,317	3,048	4,054	461	3,664	16,364
Rest of Far East	3,612	2,751	2,648	401	398	9,810
Rest of World	1,692	1,966	1,238	215	676	5,787
<b>Developing Countries</b>	<b>10,441</b>	<b>7,765</b>	<b>7,940</b>	<b>1,077</b>	<b>4,738</b>	<b>31,961</b>
<b>Total</b>	<b>23,007</b>	<b>13,009</b>	<b>15,680</b>	<b>1,999</b>	<b>17,181</b>	<b>70,876</b>

Source: Cropnosis Agrochemical Service, 2017

# Managing the risks of insect resistance associated with the use of transgenic *Bt* crops


## ***How to cope with insect resistance to Bt toxins?***

Several strategies for decreasing the rate at which insects adapt to *Bt* toxins produced in transgenic plants have been proposed and implemented . These strategies include:

- 1) engineering plants to produce *Bt* toxins only in the tissues that are prone to insect attack;
- 2) using rotations (in which transgenics may be alternated in time with non-transgenics), or mosaics (in which mixtures of transgenic and non-transgenic plants are grown together);
- 3) creating refugia in which a portion of a field may be planted with non-transgenics, or the “high dose-refuge” (HDR) strategy ;
- 4) developing resistance monitoring programmes.

# Schematic representation of the “high dose-refuge” (HDR) strategy

Mechanism of high-dose/refuge strategy to delay the increase in highly resistant (RR) insects in a pest population



The success of the HDR strategy depends on resistance being a rare and recessive trait and the genetically modified plants producing a dose of toxin sufficient to kill all homozygous susceptible individuals (SS-green) and all heterozygous individuals with for both resistance and susceptibility alleles (RS-blue)

Thank you for your attention